+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oxagen Limited - logo

Oxagen Limited is a privately-held biopharmaceutical company that works in collaboration with Eleventa LLC to develop and commercialise OC000459 for the Russian and CIS markets. OC000459 is a once-daily oral CRTH2 antagonist which has demonstrated encouraging activity in the treatment of eosinophilic asthma and allergic rhinoconjunctivitis, and an excellent safety profile. Oxagen Limited was incorporated in 1996 and is based in Abingdon, United Kingdom.

From
Asthma (Respiratory) - Drugs In Development, 2021 - Product Thumbnail Image

Asthma (Respiratory) - Drugs In Development, 2021

  • Report
  • August 2021
  • 931 Pages
From
From
From
Prostaglandin D2 Receptor 2 - Pipeline Review, H2 2019 - Product Thumbnail Image

Prostaglandin D2 Receptor 2 - Pipeline Review, H2 2019

  • Drug Pipelines
  • November 2019
  • 61 Pages
From
Prostaglandin D2 Receptor 2 - Pipeline Review, H1 2019 - Product Thumbnail Image

Prostaglandin D2 Receptor 2 - Pipeline Review, H1 2019

  • Drug Pipelines
  • June 2019
  • 57 Pages
From
  • 8 Results (Page 1 of 1)
Loading Indicator